Healthcare
Live Price
Offline$67.88
+0.55% today
1Y Change
-5.92%
Window
Jun 25, 2025 โ Jun 22, 2026
Coverage: 248 bars ยท Jun 25, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
The Cooper Companies, Inc. (COO) is a Healthcare stock with a market cap of $11.95B and listed on NASDAQ. The stock last traded around $67.88 and down 5.9% across the available one-year price window (Jun 25, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of +5.1%, EPS growth of -4.6%, a dividend yield of 0.0%. What stands out right now is revenue +5.1%, EPS -4.6%, free cash flow +50.5% with operating margin 17.2% and ROIC 4.1%. Valuation already assumes a fairly strong business story at P/E 30.0 and price/sales 2.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines COO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+5.1% vs +7.6% peer median
Operating Margin
Below sector median
+17.2% vs +19.4% peer median
P/E
Below sector median
30.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Jun 4, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +5.1% and EPS is at -4.6%, with operating margin around 17.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.5% over the next 5 trading days and finished higher after 2 of those reports.
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Jun 4, 2026 | โ | +8.6% | +8.9% | โ |
2026 Mar 5, 2026 | +6.8% | -4.6% | -10.8% | -12.5% |
2025 Dec 4, 2025 | +3.6% | +5.7% | +6.6% | +9.5% |
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
COO
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
COO Max Drawdown
-30.05%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for COO and SPY.
Company Overview
The Cooper Companies, Inc.
NASDAQ
The Cooper Companies, Inc. is a global medical device company operating through two primary segments: CooperVision and CooperSurgical. CooperVision specializes in vision care, offering a comprehensive portfolio of contact lenses including spherical, multifocal, toric, and specialty lenses under brands such as Proclear, Biofinity, MyDay, and Clariti. It serves contact lens wearers worldwide with high-quality products and practitioner support, maintaining a significant presence in the contact lens market. CooperSurgical focuses on reproductive health, fertility, and women's care, providing a broad range of medical devices that cover the entire IVF cycle, along with products like Paragard, the only hormone-free IUD available in the US. The company advances health outcomes for women, babies, and families through its diversified offerings in medical devices, fertility, and genomics. Founded in 1958 and headquartered in San Ramon, California, The Cooper Companies, Inc. plays a key role in the healthcare sector, particularly in eyecare and reproductive medicine.
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.